NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Sep 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
DETECTNET (copper cu 64 dotatate) by Curium Pharma is positron emitting activity [moa]. Approved for neuroendocrine tumors. First approved in 2020.
Drug data last refreshed 20h ago
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications (1)
Clinical Trials (1)
Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)
Neuroendocrine Tumors
Company
Worked on DETECTNET at Curium Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.